Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,587 recruiting studies in this area right now.
By phase
- Not applicable9,776
- Phase 24,446
- Phase 12,737
- Phase 1/Phase 21,691
- Phase 31,394
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,226
- Cancer660
- Prostate Cancer651
- Colorectal Cancer494
- Lung Cancer425
- Ovarian Cancer340
- Multiple Myeloma332
- Gastric Cancer298
- Acute Myeloid Leukemia292
- Pancreatic Cancer292
- Hepatocellular Carcinoma283
- Solid Tumor256
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer226
- Endometrial Cancer206
- Advanced Solid Tumors192
- Bladder Cancer192
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University312
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)287
- Mayo Clinic242
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center148
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,428
- Texas638
- Arizona513
- Florida448
- Alabama421
- New York407
- Massachusetts342
- Maryland329
- New Jersey267
- Pennsylvania245
Recruiting studies20,587 total
- NCT07390435Recruiting
Collecting social and economic data in CCTG cancer trials
This study looks at how well it works to collect information about patients' social and economic backgrounds during cancer clinical trials. If you are already in a CCTG trial or being screened for one, you may be asked to fill out a short questionnaire about things like your education, income, and housing.
Calgary, AlbertaAges 18 years+ - NCT07160725RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
Irvine, CaliforniaAges 18 years+ - NCT05391490RecruitingPhase 1
Testing donated immune cells for advanced CD19 blood cancers
This early-phase trial tests donated (allogeneic) immune cells engineered to recognize CD19, a target found on many B-cell cancers. It’s designed for people whose CD19+ cancer has come back or didn’t respond after several previous treatments, aiming to shrink tumors and control disease.
LondonAges 16–65 - NCT06391242RecruitingPhase 3
Comparing radiation treatments for painful bone metastases
This trial compares two types of radiation therapy—standard palliative radiation and a more targeted high-dose treatment (SBRT)—to see which better relieves pain from bone metastases that have spread outside the spine. It is for people with solid tumors who have a painful bone spot and are expected to live at least 6 months.
Calgary, AlbertaAges 18 years+ - NCT06666348RecruitingPhase 1/Phase 2
Mirdametinib plus vinblastine for untreated low-grade glioma
This trial tests a combination of two drugs (mirdametinib and vinblastine) for children and young adults with a type of slow-growing brain tumor called low-grade glioma that has certain genetic changes. It may be an option for people who have not received any previous treatment for their tumor.
Calgary, AlbertaAges 2–25 - NCT05201534Recruiting
Math and thinking skills training for school-age children
This trial studies interventions to improve math and cognitive (thinking) skills in elementary school children. It includes both children with math learning difficulties and typically developing children, using tests and MRI brain scans for those who can participate.
Palo Alto, CaliforniaAges 6–12 - NCT06043427RecruitingPhase 2
Testing paclitaxel and ramucirumab with or without zanidatamab for HER2+ stomach cancer
This trial tests adding a new drug (zanidatamab) to standard chemotherapy (paclitaxel and ramucirumab) for people with advanced HER2-positive stomach, gastroesophageal junction, or esophageal cancer that has worsened after previous treatment. It aims to see if the combination works better.
Calgary, AlbertaAges 18 years+ - NCT07736937RecruitingPhase 1/Phase 2
Study of TUB-040 with Standard Drugs for Ovarian Cancer
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT07358377RecruitingPhase 1
Combination therapy for HR-positive, HER2-negative cancer
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
Bowral, New South WalesAges 18 years+ - NCT06386198Recruiting
Health Advocate for Young Liver Transplant Patients
This study tests a program that helps young adults with a liver transplant prepare to move from a children’s hospital to an adult hospital. It aims to provide extra support for people who also have social needs like trouble getting enough food.
San Francisco, CaliforniaAges 18–25 - NCT07637578RecruitingPhase 2
Elranatamab infusions for relapsed or refractory myeloma
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Denver, ColoradoAges 18 years+ - NCT07603479RecruitingPhase 1
Testing JL19001 for Advanced Cancers and Lymphoma
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07342478RecruitingPhase 3
Comparing two BTK inhibitors for CLL/SLL after prior treatment
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Skokie, IllinoisAges 18 years+ - NCT07549022RecruitingPhase 1/Phase 2
Testing BMS-986504 for Unresectable Nerve Sheath Tumors
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
Cleveland, OhioAges 12 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Irving, TexasAges 18 years+ - NCT06880549RecruitingPhase 1
mRNA cancer vaccine study for advanced solid tumors
This study tests two new mRNA-based vaccines, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the vaccines are safe and can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06840834RecruitingPhase 2
New drug for mesothelioma that has returned after prior treatment
This trial tests a drug called ivonescimab for people with pleural mesothelioma (a cancer of the lung lining) that has grown back after earlier immunotherapy and chemotherapy. The drug may help by blocking a protein that tumors use to hide from the immune system, possibly slowing or shrinking the cancer.
BesançonAges 18 years+ - NCT04253964RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced lung cancer
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
Winston-Salem, North CarolinaAges 18 years+ - NCT07756437Recruiting
Blood test for detecting bladder cancer DNA
This study is testing a simple blood test that looks for cancer DNA in your blood. The goal is to see if it can accurately detect muscle-invasive bladder cancer or upper tract urothelial cancer.
Ghent, East FlandersAges 18 years+ - NCT07755449RecruitingPhase 2
Targeted radiation for head and neck cancer after surgery
This trial tests a new way of giving radiation therapy only to the side of the neck that needs it, which may reduce side effects while still preventing cancer from coming back. It is for people who have had surgery for head and neck cancer and have not had the cancer spread to the lymph nodes.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT07304934Recruiting
New blood test model to check lymph node status in breast cancer
This study uses a blood test and imaging to predict whether breast cancer has spread to underarm lymph nodes, helping guide surgery. It may reduce unnecessary lymph node removal.
Hangzhou, ZhejiangAges 18 years+ - NCT07754929Recruiting
Digital support for prostate cancer survivors' sexual and mental health
This study tests a smartphone-based program designed to help prostate cancer survivors improve their mental and sexual health. It may offer a convenient way to get support without visiting a clinic.
PortoAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,587 recruiting oncology studies from the U.S. registry right now, out of 31,171 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.